Thermo Fisher Scientific Inc. has offered to pay about $13.6 billion to buy genetic testing equipment maker Life Technologies in a cash deal that will create a giant company serving research and specialty diagnostics. Life Technologies Corp. shareholders and regulators still need to approve the acquisition.
Myriad Genetics announced that Myriad RBM, a wholly owned subsidiary of Myriad Genetics, has...
The US scientist, Marlene R. Cohen PhD, Assistant Professor in the department of neuroscience...
Reprints Desk Inc. has launched its really simple syndication (RSS) feed import functionality inside Bibliogo. The new functionality was created specifically to accommodate the needs of professionals who are seeking an alternative to Google Reader feed reader after the announcement that Google will be powering down the service in July 2013.
Diagnostic products maker Qiagen NV will work with Eli Lilly to develop new tests that could identify patients who could be helped by Lilly's drugs. The companies did not disclose terms of the new collaboration, but described it as a "broad" partnership that will cover "all therapeutic areas."
Agilent Technologies Inc. will work with Pfizer Inc. to develop diagnostic tests. Agilent announced its Dako division will help develop companion diagnostic tests, which are designed to help physicians decide how to treat patients by showing which treatments they might respond to.
Agilent Technologies Inc. announced that it will work with Pfizer Inc., the biggest drug company in the world, to develop companion diagnostic tests, which are designed to help physicians decide how to treat patients by showing which treatments they might respond to.
Rockland Immunochemicals Inc. announced the acquisition of the TrueBlot IP/Western blot product line from eBioscience, Inc., an Affymetrix company. Western blotting, a critical assay that is a widely accepted analytical technique in both scientific research and medical diagnosis, is used to determine expression and quantitate target proteins in biological samples.
Beactica has added a project under its ongoing research services agreement with Janssen Research & Development. Beactica will use its proprietary drug discovery platform Sprint to identify novel allosteric modulators targeting undisclosed central nervous system proteins of therapeutic interest to Janssen.
Capsugel announced it has doubled its laboratory capacity with the opening of a quality control laboratory in Greenwood, S.C. The laboratory serves as a global resource to its extensive network of manufacturing sites and R&D laboratories located in Boston, Strasbourg, and Colmar.
Rhenovia Pharma has filed two patent applications for RHEpatch, Rhenovia’s electronic transdermal patch for people suffering from chronic diseases. RHEpatch was originally designed to optimize the delivery of drugs to patients suffering from diseases of the nervous system.
WiCell, a leader in the cytogenetic testing of mouse and human embryonic stem cells and induced pluripotent stem cells, is offering comparative genomic hybridization plus single nucleotide polymorphism microarray analysis using the Agilent SurePrint G3 Human Genome CGH+SNP Microarray.
Agilent Technologies Inc. and SRI International announced they have signed a licensing agreement to offer laboratory research customers a package that combines Agilent’s latest release of GeneSpring GX, GeneSpring NGS, Mass Profiler Professional and Pathway Architect version 12.5 with SRI International’s complete BioCyc Pathway Database Collection.
Qiagen N.V. announces that China’s State Food and Drug Administration has approved the company’s careHPV Test and instrument platform. The careHPV Test is the first molecular diagnostic to screen for high risk human papillomavirus designed for low-resource clinical settings, such as areas lacking electricity, water, or modern laboratory infrastructure.
Gilead Sciences has announced two-year results from two pivotal Phase 3 studies (Studies 102 and 103) evaluating the company's single tablet HIV regimen, Stribild (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), among treatment-naïve patients with HIV-1 infection.
The development, monitoring, validation and revalidation of bioassays to measure the potency of biologic drugs are critical. On Dec. 4-5, 2012, the United States Pharmacopeial Convention (USP) will host the Fifth Bioassay Workshop at its headquarters in Rockville, Md., to discuss these topics.
Agilent Technologies Inc. has opened a new X-ray diffraction manufacturing facility in Wrocław, Poland. The state-of-the-art facility gives Agilent significantly greater manufacturing capacity and enhanced R&D capabilities compared with the company’s old facility.
BioCat announces the signing of an exclusive distribution agreement with ALPCO Diagnostics. The agreement names BioCat as the exclusive distributor for ALPCO products in Germany. ALPCO Diagnostics is know for their insulin ELISA kits and other market-leading metabolism assays.
PPD has signed an agreement to use Tessella and Berry Consultants' FACTS software to create a more flexible, intuitive approach for trial design. The software expands PPD's adaptive design capabilities by giving biopharmaceutical companies greater ability to use simulations to investigate study design options.
Plexpress has announced plans to extend its collaboration with Admescope. The Tracpack induction screening service is optimized for screening high priority drug candidates, producing all the data required to meet Food and Drug Administration regulations.
CEVEC Pharmaceuticals and CCS Cell Culture Service GmbH announced the signing of a strategic license agreement. The license will enable CCS to offer its customers transiently transfected CAP-T cells for cell based assay and protein production applications.
Fujifilm Diosynth Biotechnologies has announced it has entered into a strategic alliance with Piramal Healthcare UK Ltd, whereby the two parties will offer the contract development and manufacture of antibody drug conjugates, a growing niche in the development of biopharmaceuticals.
Crown Bioscience Inc. and Horizon Discovery Ltd. will highlight the availability of X-MAN cell lines for in vitro and in vivo drug discovery model validation. Human disease models are crucial for generating patient-relevant targets and facilitating the development of novel oncology targets.
IO Informatics, the leader in semantic data integration and knowledge management for life sciences and healthcare, announced it has launched its Sentient iDA in cooperation with Sage-N Research, Inc., the inventor of Integrated Data Appliance (iDA) systems.
Agilent Technologies Inc. and Roche announced the signing of an exclusive agreement to provide continued service to NimbleGen microarray customers as Roche phases out its NimbleGen array production and services. Researchers use NimbleGen microarrays for many applications.